Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Brief Summary: This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may find tumor cells and help kill them. It is not yet known whether temozolomide and radiation therapy are more effective when given together with or without bevacizumab in treating glioblastoma or gliosarcoma.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: cognitive assessment; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Calibration Arm; Type: EXPERIMENTAL; Interventions: Drug: fotemustine | Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: fotemustine; Assigned to Arm(s): Calibration Arm
C: Arm Label: Arm I (radiation therapy, temozolomide, placebo); Type: ACTIVE_COMPARATOR; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Temozolomide | Arm Label: Arm II (radiation therapy, temozolomide, bevacizumab); Type: EXPERIMENTAL; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Biological: Bevacizumab, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Temozolomide | Intervention Type: RADIATION; Name: 3-Dimensional Conformal Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: RADIATION; Name: Intensity-Modulated Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab)
D: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy

Answer: C